Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II perioperative givastomig + durvalumab + FLOT for resectable gastric, gastroesophageal junction, or esophageal adenocarcinoma
jRCT2031260312Phase 2Recruiting
- Sponsor
- National Cancer Center Hospital East
- Start
- Oct 2026
- Modality
- Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of givastomig, durvalumab, docetaxel, oxaliplatin, folinic acid and 1 more in gastric adenocarcinoma, gastroesophageal junction adenocarcinoma and esophageal adenocarcinoma (EAC), sponsored by National Cancer Center Hospital East. Primary endpoint: Major pathological response rate. Started Oct 2026; status: recruiting.
02
Drugs
givastomigdurvalumabdocetaxeloxaliplatinfolinic acid
03
Conditions
gastric adenocarcinomagastroesophageal junction adenocarcinomaesophageal adenocarcinoma (EAC)
Beyond the preview
Go deeper on jRCT2031260312.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031260312.